A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I:

##STR00001##

wherein X is —CH.sub.2—, —CH.sub.2—CH.sub.2—, —CHO—, or —O—CO—; Y is —CH—CH═CH— or

##STR00002##

A and B are independently selected from C and N; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from —H, halogen, —OH, and —CH.sub.3; and R.sub.5, R.sub.6, and R.sub.7 are independently selected from —H, halogen, —OH, —OCH.sub.3, —NO.sub.2, —N(CH.sub.3).sub.2, C.sub.1-C.sub.6 alkyl, or a substituted or unsubstituted C.sub.4-C.sub.6 aryl group, except that when A and/or B is N the adjacent R.sub.5 and/or R.sub.7 is —H, or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of phospholipid processing, in particular to a self-aggregating hydrous phospholipid and a preparation method thereof. The self-aggregating hydrous phospholipid, the main components of the self-aggregating hydrous phospholipid are phospholipids, oil and water, the water content is 70-80 g/100 g, and the acetone-insoluble content on a dry basis is 92.5-95.5 g/100 g. Preferably, the self-aggregating hydrous phospholipid is a brown translucent fluid. The present invention is used to overcome the defects of low acetone-insoluble content of the hydrous phospholipid prepared by the existing method and the long-term dependence of the industry on the solvent method to prepare powder phospholipid, and to solve the technical problem that the hydration method powder phospholipid cannot realize industrial production.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

The present application provides anandamide and 2-arachidonoyl glycerol compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating diseases or disorders are also provided.

The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Synthetic blood substitutes and methods for making them. A lipid-amphiphile blood-substitute precursor compound having a hydrophobic fatty acid/acyl moiety, a hydrophilic head moiety including a phosphate group, and a pH responsive moiety. The lipid-amphiphile precursor is configured to self-assemble from a solution mixture of phospholipid and cholesterol in the presence of hemoglobin and an allosteric effector into a hybrid-vesicle resulting from the combined self-assembly of both the amphiphilic lipid-oligomer and the lipids into an advanced vesicular structure containing a hemoglobin/allosteric effector payload.